ClinicalTrials.gov
ClinicalTrials.gov Menu

Relevance of Imiquimod as Neo-adjuvant Treatment to Reduce Excision Size and the Risk of Intralesional Excision in Lentigo Malignant of the Face (ImiReduc)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01720407
Recruitment Status : Recruiting
First Posted : November 2, 2012
Last Update Posted : July 21, 2017
Sponsor:
Collaborator:
MEDA Pharma GmbH & Co. KG
Information provided by (Responsible Party):
Nantes University Hospital

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : August 2019
  Estimated Study Completion Date : August 2022